Lexaria Bioscience (LEXX) Receivables (2010 - 2026)
Lexaria Bioscience (LEXX) posted Receivables of $113012.0 for Q2 2026, up 6.57% sequentially from $106043.0 in Q1 2026, and down 73.23% YoY from $422143.0 in Q2 2025.
Lexaria Bioscience (LEXX) Receivables (2010 - 2026) Analysis & Trends
Lexaria Bioscience has reported Receivables for 17 years, with the latest figure at $113012.0 in Q2 2026.
- Quarterly Receivables fell 73.23% year-over-year to $113012.0 in Q2 2026, while the trailing twelve-month figure through May 2026 was $113012.0 (down 73.23% YoY) and the FY2025 annual result came in at $432371.0, up 85.51% from the prior year.
- Receivables rose to $113012.0 in Q2 2026 per LEXX's latest filing, from $106043.0 in the prior quarter.
- Over five years, Receivables peaked at $583290.0 in Q4 2023 and troughed at $106043.0 in Q1 2026.
- A 5-year average of $281007.2 and a median of $248011.5 in 2024 frame the typical range for Receivables.
- The sharpest annual moves came in 2022 and 2024: Receivables plunged 83.77% in 2022, then soared 189.91% in 2024.
- Over 5 years, Receivables stood at $286322.0 in 2022, then soared by 103.72% to $583290.0 in 2023, then tumbled by 43.85% to $327505.0 in 2024, then slumped by 53.57% to $152057.0 in 2025, then retreated by 25.68% to $113012.0 in 2026.
- According to Business Quant data, Receivables over the past three periods registered $113012.0, $106043.0, and $152057.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.14 Bn | 132.29 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 87.02 Bn | 79.03 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.12 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 60.84 Bn | 55.70 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.06 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.49 Bn | 28.18 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.78 Bn | 10.38 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.14 Bn | 26.31 Bn | - | - |
| 10 | Lexaria Bioscience | 10.31 Mn | 6.70 Mn | - | 113,012.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 113,012.00 |
| Feb 28, 2026 | 106,043.00 |
| Nov 30, 2025 | 152,057.00 |
| Aug 31, 2025 | 432,371.00 |
| May 31, 2025 | 422,143.00 |
| Feb 28, 2025 | 395,180.00 |
| Nov 30, 2024 | 327,505.00 |
| Aug 31, 2024 | 218,052.00 |
| May 31, 2024 | 277,971.00 |
| Feb 29, 2024 | 396,584.00 |
| Nov 30, 2023 | 583,290.00 |
| Aug 31, 2023 | 175,245.00 |
| May 31, 2023 | 172,284.00 |
| Feb 28, 2023 | 136,796.00 |
| Nov 30, 2022 | 286,322.00 |
| Aug 31, 2022 | 201,784.00 |
| May 31, 2022 | 154,868.00 |
| Feb 28, 2022 | 506,622.00 |
| Nov 30, 2021 | 461,512.00 |
| Aug 31, 2021 | 342,401.00 |